Author's note: I present and update my best small-cap Busted IPO stock ideas only to subscribers of my exclusive marketplace, The Busted IPO Forum . Try a free 2-week trial today by clicking HERE .Shares of biopharmaceutical concern Monopar Therapeutics Inc. (NASDAQ: MNPR ) have had an absolutely massive surge in the past year after being left for dead with cash of $7.1 million and a market cap under $9 million. Its acquisition of Wilson disease candidate ALXN-1840The Busted IPO Forum is an investing group ...

"Successful investing takes time, discipline, and patience. No matter how great the talent or effort, some things just take time", said Warren Buffett. The question now is - did you have the patience to hold on to stocks we highlighted and reap the gains? Cidara Therapeutics Inc. (CDTX) touched a 52-week high of $87.19 today, as it continues to progress with its accelerated development plan for CD388, a non-vaccine preventive treatment for seasonal influenza. The company will be pursuing a Biologics Licens ...

Core Viewpoint - Monopar Therapeutics Inc. has announced a registered offering of common stock and pre-funded warrants, aiming to raise approximately $100 million for general corporate purposes, including research and development [1][2][3]. Group 1: Offering Details - The offering consists of 1,034,433 shares of common stock priced at $67.67 per share and pre-funded warrants to purchase 960,542 shares at $67.669 each [1]. - The gross proceeds from the offering, net of anticipated stock repurchase, are expected to be around $100 million before underwriting discounts and expenses [2]. - The offering is anticipated to close on or about September 25, 2025, subject to customary closing conditions [3]. Group 2: Use of Proceeds - Monopar plans to allocate up to $35 million of the proceeds to repurchase shares from Tactic Pharma, LLC at a price of $63.6098 per share, which is equivalent to the offering price for investors [3]. Group 3: Management and Registration - Morgan Stanley, Leerink Partners, and Barclays are serving as lead book-running managers for the offering [4]. - The securities are being offered under a "shelf" registration statement filed with the SEC, with a prospectus supplement to be made available [5]. Group 4: Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments, including late-stage ALXN1840 for Wilson disease and various radiopharmaceutical programs for advanced cancers [7].

Core Insights - Monopar Therapeutics Inc. announced the publication of a peer-reviewed Letter to the Editor in the Journal of Hepatology, discussing the effects of ALXN1840 on copper balance in patients with Wilson disease [1][2] Group 1: Study Findings - The earlier conclusion from the Phase 2 ALXN1840-WD-204 study indicated that ALXN1840 did not promote copper excretion due to methodological limitations in the copper balance equation [2] - The new analysis shows that ALXN1840 statistically significantly improved copper balance, increasing copper excretion over the study duration [2] - Key findings include: - For the 15 mg/day treatment period, the mean daily difference in copper balance was -0.367 mg (p=0.005) - For the overall treatment period, the mean daily difference was -0.289 mg (p=0.023) - The cumulative mean change from baseline was -6.08 mg (95% CI: -10.18 mg to -1.98 mg) [5] Group 2: Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, including late-stage ALXN1840 for Wilson disease [8] - The company also has radiopharmaceutical programs in various stages of development for imaging and treating advanced cancers [8]

Core Insights - Monopar Therapeutics Inc. announced the publication of a peer-reviewed Letter to the Editor in the Journal of Hepatology, discussing the effects of ALXN1840 on copper balance in patients with Wilson disease [1][2] Group 1: Study Findings - The earlier conclusion from the Phase 2 ALXN1840-WD-204 study indicated that ALXN1840 did not promote copper excretion due to methodological limitations in the copper balance equation [2] - By comparing pre- and post-treatment data, the analysis showed that ALXN1840 statistically significantly improved copper balance, leading to increased copper excretion [2] - Key findings from the study include: - For the 15 mg/day treatment period, the mean daily difference in copper balance was -0.367 mg (p=0.005) - For the overall treatment period, including dose changes, the mean daily difference was -0.289 mg (p=0.023) - The cumulative mean change from baseline was -6.08 mg (95% CI: -10.18 mg to -1.98 mg) [5] Group 2: Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, including late-stage ALXN1840 for Wilson disease and various radiopharmaceutical programs [8]

Core Insights - Monopar Therapeutics Inc. announced new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 for Wilson disease, to be presented at the 150th American Neurological Association Annual Meeting [1][3] - The analysis pooled efficacy outcomes from three independent clinical trials involving 255 patients, while safety data included a fourth independent clinical trial with 266 patients, with a median treatment duration of approximately 2.6 years [2] Efficacy and Safety Findings - Long-term neurological benefits of ALXN1840 were highlighted, showing sustained improvement on the Unified Wilson Disease Rating Scale (UWDRS) over 6 years [6] - Patients who switched from standard of care to ALXN1840 experienced additional neurological improvements, with many reversing previous declines [6] - Statistically significant psychiatric improvements were also sustained over multiple years, measured by the Brief Psychiatric Rating Scale (BPRS) [6] - Neurological benefits were consistently observed across multiple independent studies [6] - The safety profile of ALXN1840 was favorable, with less than 1% of patients experiencing drug-related serious adverse events over more than 645 patient-years [6] Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, including ALXN1840 for Wilson disease and various radiopharmaceutical programs [4]

Core Insights - Monopar Therapeutics Inc. announced new data on the long-term neurological efficacy and safety of its investigational therapy ALXN1840 for Wilson disease, to be presented at the 150th American Neurological Association Annual Meeting [1][3] Group 1: Efficacy and Safety Data - The analysis pooled efficacy outcomes from three independent clinical trials involving 255 patients, while safety data included a fourth independent clinical trial with 266 patients [2] - Median treatment duration with ALXN1840 was approximately 2.6 years for both efficacy and safety analyses [2] - Statistically significant neurological improvement was sustained over 6 years on the Unified Wilson Disease Rating Scale [6] - Patients who crossed over from standard of care to ALXN1840 showed additional neurological improvement, with many reversing worsened conditions [6] - Statistically significant psychiatric improvement was also sustained over multiple years, measured by the Brief Psychiatric Rating Scale [6] - Neurological benefits were consistently observed across multiple independent studies [6] - The safety profile of ALXN1840 was favorable, with less than 1% of patients experiencing drug-related neurological serious adverse events over more than 645 patient-years [6] Group 2: Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, including ALXN1840 for Wilson disease and various radiopharmaceutical programs [4]

Group 1 - The article introduces Monopar Therapeutics Inc. (NASDAQ: MNPR) and highlights its business overview as provided in its Q2 2025 report [1] - The investing group Haggerston BioHealth offers insights for both novice and experienced biotech investors, including catalysts to watch and buy/sell ratings [1] - The group also provides forecasts for product sales and integrated financial statements for major pharmaceutical companies, along with discounted cash flow analysis and market-by-market analysis [1] Group 2 - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group and has compiled detailed reports on over 1,000 companies [1]

Core Insights - Monopar Therapeutics Inc. announced that its abstract on the long-term neurological benefits of ALXN1840 in Wilson disease patients has been selected for both oral and poster presentations at the 150th American Neurological Association Annual Meeting [1][2] Company Overview - Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs, with late-stage ALXN1840 for Wilson disease and various radiopharmaceutical programs [3] Presentation Details - The abstract titled "Long-term sustained improvement of neurological symptoms in Wilson disease patients on tiomolybdate choline" has been designated as an Abstract of Distinction by the ANA [2] - The poster presentation is scheduled for September 14, 2025, and the oral presentation for September 15, 2025 [5]

[Filing Information](index=1&type=section&id=Filing%20Information) Provides essential identification details for Monopar Therapeutics Inc., including its registration, securities, and company status [Registrant Information](index=1&type=section&id=Registrant%20Information) Details Monopar Therapeutics Inc.'s fundamental identification, including incorporation state, principal offices, and contact information - Registrant: **MONOPAR THERAPEUTICS INC.**[2](index=2&type=chunk) - State of Incorporation: Delaware[3](index=3&type=chunk) - Principal Executive Offices: 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091[3](index=3&type=chunk) [Securities Registered](index=1&type=section&id=Securities%20Registered) Lists Monopar Therapeutics Inc.'s Common Stock registered under Section 12(b), including its trading symbol and exchange Registered Securities | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | :------------------ | :---------------- | :--------------------------------------- | | Common Stock, $0.001 par value | MNPR | The Nasdaq Stock Market LLC (Nasdaq Capital Market) | [Emerging Growth Company Status](index=1&type=section&id=Emerging%20Growth%20Company%20Status) Indicates that Monopar Therapeutics Inc. is not an emerging growth company - Monopar Therapeutics Inc. is not an emerging growth company[5](index=5&type=chunk) [Item 2.02 Results of Operations and Financial Condition](index=2&type=section&id=Item%202.02%20Results%20of%20Operations%20and%20Financial%20Condition) Reports the announcement of Monopar Therapeutics Inc.'s financial results for the second quarter ended June 30, 2025 [Announcement of Financial Results](index=2&type=section&id=Announcement%20of%20Financial%20Results) Monopar Therapeutics Inc. announced Q2 2025 financial results via an August 12, 2025 press release, furnished but not legally "filed" - Monopar Therapeutics Inc. issued a press release on August 12, 2025, announcing financial results for the second quarter ended June 30, 2025[6](index=6&type=chunk) - A copy of the press release is attached as Exhibit 99.1[6](index=6&type=chunk) - The information in this item and exhibit is furnished and not deemed 'filed' under Section 18 of the Securities Exchange Act of 1934[7](index=7&type=chunk) [Item 9.01 Financial Statements and Exhibits](index=2&type=section&id=Item%209.01%20Financial%20Statements%20and%20Exhibits) Provides a comprehensive list of financial statements and exhibits accompanying the filing [Exhibits List](index=2&type=section&id=Exhibits%20List) Lists all exhibits accompanying the Form 8-K filing, including the press release and interactive data file Exhibits | Exhibit No. | Description | | :------------ | :---------------------------------------------------- | | 99.1 | Press Release Dated August 12, 2025 | | 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | [Signature](index=3&type=section&id=Signature) Confirms the official authorization and signatory details for the filed report [Authorization and Signatory](index=3&type=section&id=Authorization%20and%20Signatory) The report is duly signed on behalf of Monopar Therapeutics Inc. by its Chief Financial Officer, Quan Vu, confirming authorization - The report was signed on August 12, 2025[12](index=12&type=chunk) - Signatory: Quan Vu, Chief Financial Officer of Monopar Therapeutics Inc.[12](index=12&type=chunk)